MedTrace Logo

Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block

NCT05228223 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-02-08

No results posted yet for this study

Summary

In this prospective randomized controlled study the investigators compare the sugammadex-neostigmine combination and single dose sugammadex in terms of side effects and cost for the antagonism of moderate neuromuscular block induced by rocuronium.

Conditions

  • Residual Neuromuscular Block
  • Neuromuscular Blockade Monitoring

Interventions

DIAGNOSTIC_TEST

Neuromuscular monitoring

TOF monitoring

OTHER

reverse of NMB with sugammadex

Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.

OTHER

reverse of NMB with Sugammadex and neostigmin low dose

Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg

OTHER

reverse of NMB with Sugammadex and neostigmin high dose

patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    lead OTHER

Principal Investigators

  • Aysun Postacı · Ankara City Hospital Bilkent

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-05-31
Completion
2022-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05228223 on ClinicalTrials.gov